Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of Immunotherapy Combination Strategies in Cancer
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, et al.
Cancer Discovery (2021) Vol. 11, Iss. 6, pp. 1368-1397
Open Access | Times Cited: 232

Showing 1-25 of 232 citing articles:

Immunotherapy: Reshape the Tumor Immune Microenvironment
Bingzhe LV, Yunpeng Wang, Dongjiang Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 246
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Marilyne Labrie, Joan S. Brugge, Gordon B. Mills, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 323-339
Open Access | Times Cited: 217
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Huailiang Wu, Yue Gong, Peng Ji, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 104
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
Ming Yi, Mengke Niu, Jing Zhang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 102
Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication
Lucas A. Horn, Paul L. Chariou, Sofia R. Gameiro, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 8
Open Access | Times Cited: 80
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria
Xiaoqing Xie, Yi Yang, Qiang Wang, et al.
Cell Research (2023) Vol. 33, Iss. 3, pp. 215-228
Open Access | Times Cited: 54
Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials
Bin Li, Juan Jin, Duancheng Guo, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2858-2858
Open Access | Times Cited: 53
Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids
Yunuo Mao, Wei Wang, Jingwei Yang, et al.
Protein & Cell (2023) Vol. 15, Iss. 4, pp. 285-304
Open Access | Times Cited: 48
Immune checkpoint inhibitor combinations—current and emerging strategies
Robert J. Walsh, Raghav Sundar, Joline S.J. Lim
British Journal of Cancer (2023) Vol. 128, Iss. 8, pp. 1415-1417
Open Access | Times Cited: 47
Immunologic tumor microenvironment modulators for turning cold tumors hot
Gholamreza Khosravi, Samaneh Mostafavi, Sanaz Bastan, et al.
Cancer Communications (2024) Vol. 44, Iss. 5, pp. 521-553
Open Access | Times Cited: 47
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 30
Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer
Daniiar Dyikanov, A. V. Zaitsev, Т.В. Васильева, et al.
Cancer Cell (2024) Vol. 42, Iss. 5, pp. 759-779.e12
Open Access | Times Cited: 20
Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
Young‐Jin Choi, Su Hyun Seok, Hong Yeol Yoon, et al.
Advanced Drug Delivery Reviews (2024) Vol. 209, pp. 115306-115306
Open Access | Times Cited: 19
Engineered Bio‐Based Hydrogels for Cancer Immunotherapy
Yuxuan Peng, Shuang Liang, Qian‐Fang Meng, et al.
Advanced Materials (2024) Vol. 36, Iss. 21
Closed Access | Times Cited: 18
Enhanced Photodynamic Therapy Synergizing with Inhibition of Tumor Neutrophil Ferroptosis Boosts Anti‐PD‐1 Therapy of Gastric Cancer
Xudong Zhu, Wenxuan Zheng, Xingzhou Wang, et al.
Advanced Science (2024) Vol. 11, Iss. 12
Open Access | Times Cited: 17
Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy
Yuzhu Hu, Wen Nie, Liang Lyu, et al.
ACS Nano (2024) Vol. 18, Iss. 4, pp. 3295-3312
Closed Access | Times Cited: 16
PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy
Rui Liu, Huifang Li, Shu Li
Cell Insight (2024) Vol. 3, Iss. 2, pp. 100146-100146
Open Access | Times Cited: 16
Mitochondria-targeted photodynamic therapy triggers GSDME-mediated pyroptosis and sensitizes anti-PD-1 therapy in colorectal cancer
Yun Zhou, Wenyao Zhang, Boda Wang, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008054-e008054
Open Access | Times Cited: 16
The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy
Dongming Li, Donghui Cao, Yuanlin Sun, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 15
CD73/adenosine dynamics in treatment-induced pneumonitis: balancing efficacy with risks of adverse events in combined radio-immunotherapies
Lena Gockeln, Florian Wirsdörfer, Verena Jendrossek
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 1
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression
Jinti Lin, Ankai Xu, Jiakang Jin, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 56
Clinically approved combination immunotherapy: Current status, limitations, and future perspective
Ligong Lu, Meixiao Zhan, Xian-Yang Li, et al.
Current Research in Immunology (2022) Vol. 3, pp. 118-127
Open Access | Times Cited: 45
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 17, pp. 3695-3708
Open Access | Times Cited: 44
Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review
Nuo-Han Wang, Zheng Lei, Hao-Nan Yang, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 24, pp. 1406-1406
Open Access | Times Cited: 43
Nanoplatform-mediated calcium overload for cancer therapy
Junlie Yao, Hao Peng, Yue Qiu, et al.
Journal of Materials Chemistry B (2022) Vol. 10, Iss. 10, pp. 1508-1519
Closed Access | Times Cited: 39
Page 1 - Next Page

Scroll to top